Cellectar Biosciences Management
Management criteria checks 2/4
Cellectar Biosciences' CEO is Jim Caruso, appointed in Jun 2015, has a tenure of 8.92 years. total yearly compensation is $1.97M, comprised of 30.5% salary and 69.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth €143.89K. The average tenure of the management team and the board of directors is 2.3 years and 8 years respectively.
Key information
Jim Caruso
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 30.5% |
| CEO tenure | 8.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$51m |
| Dec 31 2023 | US$2m | US$600k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$38m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$1m | US$569k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$2m | US$523k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$20m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$1m | US$475k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$15m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$934k | US$451k | -US$14m |
| Sep 30 2019 | n/a | n/a | -US$15m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$770k | US$425k | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$17m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$994k | US$410k | -US$15m |
Compensation vs Market: Jim's total compensation ($USD1.97M) is above average for companies of similar size in the German market ($USD384.52K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
CEO
Jim Caruso (64 yo)
8.9yrs
Tenure
US$1,965,140
Compensation
Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executiv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.9yrs | US$1.97m | 0.14% $ 143.9k | |
| VP, CFO & Secretary | 2.3yrs | US$1.11m | 0.12% $ 124.4k | |
| Chief Operating Officer | 2.3yrs | US$1.36m | 0.15% $ 155.3k | |
| Chief Commercial Officer | 1.5yrs | no data | 0.11% $ 115.7k | |
| Senior Vice President of Medical | 1.3yrs | no data | 0.15% $ 160.8k |
2.3yrs
Average Tenure
51yo
Average Age
Experienced Management: NV4's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.9yrs | US$1.97m | 0.14% $ 143.9k | |
| Independent Director | 16.3yrs | US$93.25k | 0.017% $ 18.3k | |
| Independent Director | 7.1yrs | US$93.25k | 0.0054% $ 5.7k | |
| Independent Director | 8.9yrs | US$93.25k | 0% $ 0 | |
| Independent Chairman of the Board | 7.1yrs | US$109.88k | 0.0070% $ 7.3k | |
| Independent Director | 2.9yrs | US$48.25k | 0% $ 0 |
8.0yrs
Average Tenure
61.5yo
Average Age
Experienced Board: NV4's board of directors are considered experienced (8 years average tenure).